Abstract
Single-agent Pembrolizumab is a first-line standard-of-care regimen for non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (≥ 50%). Venous thromboembolic events (VTE) defined both as deep vein thrombosis (DVT) or pulmonary embolism (PE) contributes to morbidity and mortality in NSCLC patients. Limited data are available regarding VTE in advanced NSCLC patients treated with first-line Pembrolizumab. Our retrospective study aimed to describe VTE incidence and its impact on survival.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
